CNBC·
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Summary
- Novo released full results from a late-stage trial showing Wegovy helped children ages 6 to under 12 with obesity lose weight & significantly lower their body mass index.
- Wegovy reduced BMI by an estimated 19.7 percentage points on average compared with a placebo at 68 weeks, with BMI falling 17.4% among children receiving the drug & rising 2.2% among those receiving a placebo.
- When evaluating all children in the study, including those who discontinued treatment, Wegovy lowered BMI by an estimated average of 16.2 percentage points more than the placebo at 68 weeks.
- All 167 kids in the study received lifestyle modifications throughout the trial, including a reduced-calorie diet & increased physical activity.
- Childhood obesity is a chronic disease that can carry serious cardiovascular, metabolic & psychosocial consequences but has had few treatment options for younger children.
- In 2025, the disease affected an estimated roughly 177 million children & teens ages 5 to 19 worldwide, a figure projected to rise to 228 million by 2040.
- Wegovy is already approved to treat obesity in children ages 12 & older, but there are currently no approved medications for those under 12.
- 85% of children in Novo's trial started with moderate to severe obesity, corresponding to BMI thresholds of 35 & above & 40 or higher, respectively.
- Nearly half of the children already had at least one obesity-related complication, such as high blood pressure, high cholesterol, or sleep apnea.
- More than 40% of children treated with Wegovy were no longer classified as having obesity after 68 weeks of the trial, assuming patients stayed on treatment.
- Novo stated Wegovy's overall safety & tolerability among children were consistent with those seen in trials with adults.
- The company observed no safety concerns related to growth or pubertal development in the kids.
- The two-year study does not establish whether treating obesity earlier can change its long-term trajectory or what treatment & maintenance might look like as children grow into adulthood.
Wegovy is already approved to treat obesity in children ages 12 and older, but there are currently no approved medications for those under 12.
- Keywords
- Breaking News: Business,Health care industry,Pharmaceuticals,Biotech and Pharmaceuticals,Biotechnology,Business,Novo Nordisk A/S,Medication,Novo Nordisk A/S,Science,iShares MSCI Denmark ETF,business news